Aytu BioScience, Inc. AYTU 深 滬
等待開盤 09-23 09:30:00 美东时间
2.49
+0.050
+2.05%
華盛通- 最 高2.57
- 今 開2.49
- 成交量 30.40万股
- 最 低 2.43
- 昨 收 2.44
- 總市值 2235.25万
- 52周最高 2.82
- 市盈率 靜 --
- 換手率 3.39%
- 52周最低 0.95
- 委 比 -90.14%
- 總股本 897.69万
- 歷史最高 12920.00
- 量 比 1.60
- 振 幅 5.74%
- 歷史最低 0.95
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aytu BioPharma FQ4 2025 Earnings Preview
Aytu BioPharma (NASDAQ:AYTU) is scheduled to announce FQ4 earnings results on Tuesday, September 23rd, after market close. The consensus EPS Estimate is -$0.06 and the consensus Revenue Estimate is $1...
今天 05:35
Earnings Outlook For Aytu BioPharma
Aytu BioPharma (NASDAQ:AYTU) is preparing to release its quarterly earnings on ...
09-22 22:02
FDA Issues Warning To Aytu Biopharma Over Misleading Ads For ADHD Drug Adzenys XR-ODT
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aytu-biopharma-716599-09092025
09-17 00:24
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock rose 25.5% to $2.66 during Monday's afte...
09-16 05:06
Aytu BioPharma Transfers Rights To AR101 Back To EnzCo, Ending Development And Terminating Rumpus Agreement With No Further Obligations
As previously disclosed in its United States Securities and Exchange Commission filings, Aytu BioPharma, Inc. (the "Company") suspended its clinical development of AR101. In connection with this suspension, the Company
08-08 05:51
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
Lake Street Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $8
Lake Street analyst Thomas Flaten initiates coverage on Aytu BioPharma (NASDAQ:AYTU) with a Buy rating and announces Price Target of $8.
07-01 22:47
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
Aytu BioPharma Expands And Extends Lending Agreement With Eclipse Business Capital, Providing Added Working Capital Flexibility As Aytu Prepares For Commercial Launch Of EXXUA Extended-Release Tablets
Term loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 million currentlyExpanded revolving line of credit facility by $1.5 millionExpanded facilities
06-23 20:14
Aytu BioPharma Closes $16.6M Stock Offering for EXXUA
Aytu BioScience ( ($AYTU) ) has provided an announcement. On June 9, 2025, Aytu...
06-10 05:07
